Investors will focus on updates on its novel CDK inhibitor, fadraciclib, when
Cyclacel Pharmaceuticals, Inc. ( CYCC Quick Quote CYCC - Free Report) reports second-quarter 2020 results.
Cyclacel’s stock has lost 66.8% in the year so far against the
industry's growth of 7.4%.
The company beat earnings expectations by 47.14% in the last reported quarter. Over the trailing four quarters, it surpassed earnings estimates on two occasions and missed in the other two, the average surprise being 14.77%.
Let us see how things have shaped up prior to this announcement.
Factors in Focus
Cyclacel is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. Being a clinical-stage company, the focus is primarily on pipeline progress.
The company currently has three programs in development. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST) is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients.
The primary focus is on the transcriptional regulation program, wherein the company is evaluating fadraciclib in multiple studies.
Cyclacel had previously reported that a heavily pretreated patient with MCL1 amplified endometrial cancer achieved a radiographically confirmed partial response (PR) after a month and a half on fadraciclib 213mg. This patient continues with the therapy and a reduction of 79% has been witnessed in her target tumor lesions after nine months. An additional patient with cyclin E amplified ovarian cancer achieved stable disease with 29% tumor shrinkage after approximately four months on the candidate at 213mg. Consequently, the company is designing a phase I/II precision medicine study to further evaluate fadraciclib as monotherapy and in combinations in patients with advanced solid tumors. Updates on the same are expected when it reports second-quarter results.
Updates on other ongoing studies will also be in focus.
Meanwhile, R&D expenses were $1.1 million in the first quarter and the same is likely to have been higher in the second quarter due to ongoing studies.
Our proven model does not conclusively predict an earnings beat for Cyclacel this time around. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Cyclacel is 0.00%.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Translate Bio (
TBIO Quick Quote TBIO - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #2. You can see . the complete list of today’s Zacks #1 Rank stocks here
QURE Quick Quote QURE - Free Report) has an Earnings ESP of +60.69% and a Zacks Rank #2.
Arena Pharmaceuticals, Inc. (
ARNA Quick Quote ARNA - Free Report) has an Earnings ESP of +12.88% and a Zacks Rank #3. These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early. See the 5 high-tech stocks now>>